[Galsulfase (Naglazyme) for the treatment of mucopolysaccharidosis type VI]
Comite d'Avaluacio de Medicaments d'Utilitzacio Hospitalaria (CAMUH)
Record ID 32010000705
Catalan
Authors' objectives:
To assess the efficacy, safety and efficiency of galsulfase compared to any other treatment alternatives, including placebo, in the treatment of patients with MPS VI.
Authors' recommendations:
Galsulfase is the only pharmacological treatment approved for patients with MPS VI. Its efficacy has been proven in the short and mid-term when compared to placebo in terms of improvements in the distance walked in the 12 minute walk test. The clinical relevance of the results is unknown.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.gencat.cat/salut/depsan/units/aatrm/pdf/galsulfasa_mucopolisacaridosivi_aatrm2010ca.pdf
URL for additional information:
http://www.gencat.cat/salut/depsan/units/aatrm/pdf/galsulfasa_recomanacions_aatrm2010ca.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Humans
- N-Acetylgalactosamine-4-Sulfatase
- Recombinant Proteins
- Mucopolysaccharidoses
Contact
Organisation Name:
Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address:
Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Contact Email:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Copyright:
Catalan Agency for Health Technology Assessment and Research (CAHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.